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Abstract
COVID-19 caused by SARS-CoV-2 poses a major threat to the global community, particularly in Indonesia.
Countermeasures to prevent the spread of this disease have also been implemented, including the implementation of a
vaccination program. An immunoassay technique that can be used to analyze antibodies that might develop following
vaccination is the indirect enzyme-linked immunosorbent assay (ELISA). We produced the recombinant spike protein
used in this study. The optimization comprised adjusted concentrations of spike recombinant protein (5 and 10 ng/mL),
blocking agent (2.5% and 5%), and conjugate (1:1000 and 1:5000). The optimal conditions in this study included a spiked
concentration of 10 ng/mL, a blocking agent concentration of 5%, sample dilution of 1:33, and a conjugate concentration
of 1:1000. The intra-assay value of this optimized indirect ELISA was 7.3, and the inter-assay value was 5.3. The
commercial MyBioSource kit and immunodiagnostic were utilized as a reference in the T-test, with P-values of 0 and
0.313, indicating that the recombinant protein in-house ELISA kit in this study demonstrated the same ability as the
commercial immunodiagnostic kit in detecting SARS-CoV-2 antibodies, allowing it to be used for post-vaccination
efficacy evaluation.
Keywords: ELISA, immunoassay, RBD protein, SARS-CoV-2, Spike

A new coronavirus surfaced in December 2019 as a cause
of severe respiratory sickness and quickly spread,
causing a worldwide epidemic, including Indonesia.
Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2)
is due to a novel coronavirus in the β-coronavirus family.
SARS-CoV-2 has a total length of 1,273 amino acids, and
it is made up of signal peptides at the N-terminus, S1
subunit, and S2 subunit. The receptor binding domain
(RBD) is found in the S1 subunit, and it is an essential
component during infection [7]. During viral infections,
RBD proteins are useful in mediating receptor
identification, cell attachment, and fusion [8, 9]. SARSCoV-2 has been reported in Indonesia since March 1,
2020, and the number of patients with COVID-19 in
Indonesia reached 1.2 million until February 20, 2021
[10]. Vaccination is a method for preventing the spread
of SARS-CoV-2, and it is considered successful if the
antibodies required to fight the disease have been
transmitted and have neutralized the virus that infects the
body. In this case, ELISA may be used to identify the
presence of these antibodies, and antibody testing using

Introduction
An immunoassay is a bioanalytic technique for detecting
the presence of a macromolecule or a small molecule in
a solution using an antibody or an antigen [1]. Given its
advantages, such as test’s sensitivity, durability, and low
cost, immunoassay enables most laboratories to promptly
and consistently diagnose illnesses. The main principle
of the immunoassay technique depends on the ability of
antibodies to recognize and bind to specific molecules,
such as antigens [2]. The enzyme-linked immunosorbent
assay (ELISA) is a popular immunoassay based on the
specific interaction between antigen and enzyme. Apart
from being sensitive and specific, ELISA is a relatively
quick test with high affinity and low cost [3]. ELISA can
be used to identify viral proteins (such as viral components), antibodies, and hormones [4,5]. Furthermore,
ELISA can be used to identify the presence of food
allergens [6].
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ELISA will be required as a form of review of
government’s vaccination program.
In this study, we developed an ELISA based on an inhouse RBD SARS-CoV-2 recombinant protein as
antigens. We have worked on the development of the
Spike SARS-CoV-2 recombinant protein. The plates
were initially coated with protein recombinant SARSCoV-2 RBD. Then the antibodies in the serum sample,
which recognize the antigen, will bind to the ELISA
microtiter plate. The RBD recombinant protein of SARSCoV-2 is an antigen used to detect COVID-19 antibodies.
The SARS-CoV-2 S protein, such as other coronaviruses,
is involved in receptor recognition, cell binding, and
fusion during viral infection [10]. A detailed study was
conducted to build a precise and accurate ELISA method
and showed its ability to determine the best series to
detect COVID-19 antibodies. The development of an
ELISA method for detecting SARS-CoV-2 antibodies
has already been carried out by utilizing recombinant
full-length nucleocapsid protein [11] and recombinant
full-length spike protein [12]. In this study, we only used
a specific area of the RBD protein on the SARS-CoV-2
spike protein.

Materials and Methods
Serum samples of vaccinated and recovered individuals
(n = 6) were utilized in this study. The subjects in this
trial had received two doses of the vaccination and had
not received the booster shot. Six of these subjects with
ages ranging from 34 to 52 years were vaccinated with
the Sinovac vaccine. Three of the participants were
COVID-19 survivors who were fully vaccinated and
infected with SARS-CoV-2 between December 2020 and
January 2021. The other three had no history of COVID19 infection and had also been fully vaccinated. No
history of comorbidity was reported among the subjects.
The study was approved by IPB’s Human Ethics
Committee number 494/IT3.KEPMSM-IPB/SK/2021.
All the participants provided informed consent to
participate and their samples for the study. Serum
samples were collected, heat inactivated at 56 °C for 30
min, and stored at −80 °C until being used [13].

In this study, we used the in-house RBD SARS Cov2
recombinant protein developed by other researchers in
our research team. A synthetic gene (GeneBank
MZ306692.1) encoding the RBD protein was expressed
in the E. coli BL21 DE3 expression system using the
pET17 vector. The purification of RBD recombinant
protein expression was accomplished by affinity
chromatography and dialysis. The SDS-PAGE device
(Biorad) was used to analyze the quality of RBD
recombinant protein expression. Commercial kits were
used in this research for comparison, including
MyBioSource ELISA Kit Cat No. MBS2614310 and
immunodiagnostic ELISA Kit Cat No. 41A235.
In this study, SARS-CoV-2 recombinant RBD proteins
were coated in different concentrations of 5 and 10
ng/mL per well to evaluate optimization. The plate was
then incubated at 4 °C for 18 h. After incubation, the
microplate was washed four times with a microplate
washer. The blocking agent used in this optimization was
skim milk (Blotto) at 2.5% and 5% concentrations. A
blocking agent solution of 300 μL was added to each well
and incubated at 37 °C for 1 h. The microplates were then
washed four times using a microplate washer. Next,
samples were inactivated. Meanwhile, standard spike
antibodies were diluted to the following concentrations:
2.4, 1.2, 0.6, and 0.3 IU/mL. One hundred microliters of
samples, calibrators, and controls were added to a
designated well and incubated at 37 °C for 1 h. The plate
was washed as previously described. Anti-human IgG
peroxidase-conjugated secondary antibody was diluted in
phosphate-buffered saline in ratios of 1:1000 and 1:5000,
and 100 μL of the solution was added to each well. The
microplates were washed four times using a microplate
washer after an hour for incubation at 37 °C. Chromogen
3,3′,5,5′-Tetramethyl-benzidine was added at 100 μL per
well and incubated for 20 min at room temperature in a
dark room. The reaction was stopped by adding 2 N
H2SO4, and the results were analyzed using a microplate
reader at 450 nm. Furthermore, ELISA was conducted 10
times. We performed two-sample T-test for data analysis.

Table 1. The Medium Carbon Steel’s Chemical Compositions

Sample
HU1
HU5
HU6
HU8
HU10
HU12

Subject Identity

Age

Gender

Date of Infection

S+V
S+V
S+V
V
V
V

34
52
50
47
37
43

Female
Female
Female
Male
Female
Male

January 21, 2021
December 30, 2020
January 12, 2021
-

Gene Target
HEX (E)
FAM (RdRp)
33.83
34.73
32.92
31.93
23.06
23.87
-

Abbreviations: S, COVID-19 survivors; V, fully vaccinated.
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Results and Discussions
This study aimed to develop and optimize an ELISA kit
for the detection of SARS-CoV-2 antibody with in-house
recombinant RBD protein. This development was
obtained systematically by considering the antigen
concentration, blocking agent concentration, sample
dilution, conjugate dilution, and calculating the interassay and intra-assay values [14, 15]. On the basis of the
analysis of six serum samples, the results of in-house
ELISA revealed that the optimal working conditions were
as follows: 10 ng per well for coating, 5% blocking agent,
1:33 of sample dilution, and 1:1000 of conjugate dilution.
An inadequate blocking concentration leads secondary
antibodies to establish non-specific binding with
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antigens, resulting in excessive background signals and
limited sensitivity [16]. This protocol was used for all
subsequent experiments (Figure 1).
We determined the coefficient of variability (CV) of this
ELISA method after identifying the ideal parameters
(Table 1). The CV was calculated to express the precision
or repeatability of the test results of the immunoassay,
which were described with regard to intra-assay and
inter-assay values, which were 7.3 and 5.3, respectively.
In addition, the acceptable intra-assay and inter-assay
values were less than 10% and 15%, respectively [17],
indicating that the ELISA kit can be consistent even
when used in a variety of circumstances and in repeated
tests.

Figure 1. Optimization of an Indirect ELISA Utilizing SARS-CoV-2 RBD Protein. Graphic (A) Blocking Agent of 2.5%, Conjugate Dilution of 1:1000, with 5 and 10 ng of RBD Protein Concentrations. Graphic (B) Blocking Agent of 5%,
Conjugate Dilution of 1:1000, with 5 and 10 ng of RBD Protein Concentrations. Graphic (C) Blocking Agent 2.5%,
Conjugate Dilution 1:5000, with 5 and 10 ng of RBD Protein Concentrations. Graphic (D) Blocking Agent 5%, Conjugate Dilution 1:5000, with 5 and 10 ng of RBD Protein Concentrations. The Orange and Blue Lines Indicate 5 and
10 ng/mL of Recombinant Protein Concentrations, Respectively

Table 2. Mean Intra-Assay and Inter-Assay Percentage Coefficients of Variation (CVs) for Serum Samples

Serum Sample

% CV Intra-assay

% CV Inter-assay

7.3

5.3

Table 3. Antibody Concentration of Each Sample
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Sample

MyBioSource Cat No.
MBS2614310 (U/mL)

Immunodiagnostic ELISA Kit
Cat No. 41A235 (IU/mL)

In-house ELISA Kit with RBD
Recombinant Protein (IU/mL)

HU1

−12.305

4.199

0.947

HU5

−7.559

3.686

1.115

HU6

−9.762

2.862

0.995

HU8

−9.254

0.032

0.987

HU10

−11.457

−0.102

0.883

HU12

−7.559

0.011

0.133

We compared our in-house ELISA kit with two
commercial kits, namely, MyBioSource ELISA Kit Cat
No. MBS2614310 and immunodiagnostic ELISA Kit Cat
No. 41A235. The results of this concentration were
calculated statistically using the T-test. Based on the Ttest results, the P-value for the in-house ELISA kit was 0
compared with the MyBioSource RBD kit, indicating a
significant difference between the two kits. Meanwhile,
the P-value for the in-house ELISA kit compared with
the RBD immunodiagnostic kit was 0.313, indicating that
no statistically significant difference was found between
the two kits. The P-value between the RBD protein inhouse ELISA kit and the immunodiagnostic ELISA kit
was higher than 0.05, indicating that the ability of the
recombinant protein in-house ELISA kit to detect SARSCoV-2 antibodies was similar to the performance of the
immunodiagnostic ELISA kit.
In this study, RBD is the domain of SARS-CoV-2, which
was used as a plate coating. It could elicit a neutralization
reaction from antibodies, which can be evaluated to
determine the extent to which it affects the immune
system [18, 19]. The concentration of the sample tested
using the MyBioSource ELISA kit showed a negative
result, indicating that the kit had poor performance in
detecting the presence of antibodies in serum.
Meanwhile, the immunodiagnostic ELISA kit and
recombinant RBD protein in-house ELISA kit showed
good results in detecting antibodies in serum, although
the two kits had differences in the amount of antibodies
present. Neutralizing antibodies will have a high affinity
for RBD, and the neutralization mechanism will be the
attachment of antibody’s heavy chain to RBD’s receptor
binding motif and the suppression of the loop region,
preventing the virus from infecting the host [20]. We
used RBD as a research material because of its
immunogenic characteristics. Apart from the RBD
protein in SARS-CoV-2, other structural proteins, such
as membrane, envelope, and nucleocapsid proteins, may
be used for the development of future ELISA approaches.
However, the need for high-quality testing methods
remains expensive. Thus, developing such methods is
needed in the current conditions. Several ELISA kits for
antibody detection against SARS-CoV-2 have been
Makara J. Sci.

created worldwide [21, 22, 23, 24]. The ELISA
methodology reported in this work allows for the
detection of RBD human anti-SARS-CoV-2 IgG
antibodies. This in-house ELISA method would be
useful for a variety of diagnostic and epidemiological
purposes.

Conclusions
The best conditions for the in-house ELISA kit for RBD
recombinant proteins were antigen concentration of 10
ng, blocking agent concentration of 5%, and conjugate
dilution of 1:1000. The inter-assay value of the recombinant RBD protein in-house ELISA was <15%, indicating
that the ELISA kit can be consistent even when performed under diverse settings. The intra-assay ELISA inhouse recombinant RBD and N protein value is <10%,
indicating that the test kit is consistent in repeated testing.
The P-value difference between the recombinant RBD
protein in-house ELISA kit and the immunodiagnostic
ELISA kit is greater than 0.05, indicating that the recombinant protein in-house ELISA kit detects SARS-CoV-2
antibodies similar to the immunodiagnostic ELISA kit,
which can be used to evaluate post-vaccination success.
However, further tests must be conducted to determine
the ability of antibodies produced after vaccination to
neutralize SARS-CoV-2 through the serum neutralization test.
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